Indications for: MYRBETRIQ GRANULES
Neurogenic detrusor overactivity (NDO) in pediatric patients aged ≥3yrs.
<3yrs: not established. Measure and dissolve granules with 100mL of water. Take with food once daily. ≥3yrs (11–<22kg): Initially 3mL (24mg), max 6mL (48mg); (22–<35kg): Initially 4mL (32mg), max 8mL (64mg); (≥35kg): Initially 6mL (48mg), may increase to max 10mL (80mg) after 4–8 weeks if needed. Severe renal impairment or moderate hepatic impairment: (11–<22kg): max 3mL (24mg); (22–<35kg): max 4mL (32mg); (≥35kg): max 6mL (48mg). ESRD, requiring dialysis, or severe hepatic impairment: not recommended.
MYRBETRIQ GRANULES Warnings/Precautions:
Do not substitute tabs and granules on a mg-per-mg basis. Severe uncontrolled hypertension: not recommended. Monitor blood pressure periodically. Significant bladder outlet obstruction, patients taking antimuscarinic drugs for OAB: risk of urinary retention. Discontinue and treat if angioedema of the tongue, hypopharynx, or larynx occurs. Pregnancy. Nursing mothers.
MYRBETRIQ GRANULES Classification:
Beta-3 adrenergic agonist.
MYRBETRIQ GRANULES Interactions:
May potentiate CYP2D6 substrates (eg, metoprolol, desipramine); adjust dose and monitor esp. with narrow therapeutic index drugs (eg, thioridazine, flecainide, propafenone). Concomitant digoxin: use lowest digoxin dose initially (monitor and titrate).
Adults: hypertension, nasopharyngitis, UTI, headache; also with solifenacin: dry mouth, constipation, tachycardia. Children: UTI, nasopharyngitis, constipation, headache.
Generic Drug Availability:
Tabs—30, 90; Granules—1